Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer

Open access
Narayan, Soumil, Bader, Gary D., Reimand, Jüri · 2016 · Genome Medicine

Abstract

BACKGROUND: Discovery of cancer drivers is a major goal of cancer research. Driver genes and pathways are often predicted using mutation frequency, assuming that statistically significant recurrence of specific somatic mutations across independent samples indicates their importance in cancer. However, many mutations, including known cancer drivers, are not observed at high frequency. Fortunately, abundant information is available about functional "active sites" in proteins that can be integrated with mutations to predict cancer driver genes, even based on low frequency mutations. Further, considering active site information predicts detailed biochemical mechanisms impacted by the mutations. Post-translational modifications (PTMs) are active sites that are regulatory switches in proteins and pathways. We analyzed acetylation and ubiquitination, two important PTM types often involved in chromatin organization and protein degradation, to find proteins that are significantly affected by tumor somatic mutations. METHODS: We performed computational analyses of acetylation and ubiquitination sites in a pan-cancer dataset of 3200 tumor samples from The Cancer Genome Atlas (TCGA). These analyses were targeted at different levels of biological organization including individual genes, pathway annotated gene sets, and protein-protein interaction networks. RESULTS: Acetylation and ubiquitination site mutations are enriched in cancer with significantly stronger evolutionary conservation and accumulation in protein domains. Gene-focused analysis with the ActiveDriver method reveals significant co-occurrences of acetylation and ubiquitination PTMs and mutation hotspots in known oncoproteins (TP53, AKT1, IDH1) and highlights candidate cancer driver genes with PTM-related mechanisms (e.g. several histone proteins and the splicing factor SF3B1). Pathway analysis shows that PTM mutations in acetylation and ubiquitination sites accumulate in cancer-related processes such as cell cycle, apoptosis, chromatin regulation, and metabolism. Integrated mutation analysis of clinical information and protein interaction networks suggests that many PTM-specific mutations associate with decreased patient survival. CONCLUSIONS: Mutation analysis of acetylation and ubiquitination PTM sites reveals their importance in cancer. As PTM networks are increasingly mapped and related enzymes are often druggable, deeper investigation of specific associated mutations may lead to the discovery of treatment-relevant cellular mechanisms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13073-016-0311-2

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Importance of cancer mutations in post-translational modification (PTM) sites of acetylation and ubiquitination. a Cancer mutations in protein acetylation sites are significantly more frequent than non-modified protein sequence, while ubiquitination sites show expected mutation rates. PTM sites include central lysine residues and ±7 flanking windows. Comparisons only include proteins with respective PTM sites. b Ubiquitination sites are enriched in protein sequences associated with structured regions, while acetylation sites are evenly distributed among structured and disordered regions. c PTM-associated cancer mutations show greater evolutionary conservation than non-PTM mutations. Disordered and structured protein sequences are compared separately. d PTM-associated cancer mutations are more frequently predicted deleterious by an ensemble of five variant function predictors
Fig. 1 Importance of cancer mutations in post-translational modification (PTM) sites of acetylation and ubiquitination. a Cancer mutations in protein acetylation sites are significantly more frequent than non-modified protein sequence, while ubiquitination sites show expected mutation rates. PTM sites include central lysine residues and ±7 flanking windows. Comparisons only include proteins with respective PTM sites. b Ubiquitination sites are enriched in protein sequences associated with structured regions, while acetylation sites are evenly distributed among structured and disordered regions. c PTM-associated cancer mutations show greater evolutionary conservation than non-PTM mutations. Disordered and structured protein sequences are compared separately. d PTM-associated cancer mutations are more frequently predicted deleterious by an ensemble of five variant function predictorsCC BY · PubMed Central
Fig. 2 Cancer genes with significant mutations in PTM sites. a ActiveDriver predicts cancer driver genes with significant co-occurrence of PTM sites and mutations. Genes are ranked by statistical significance. Known PTM enzymes associated with mutated PTM sites are shown on top of bars. Known cancer genes are highlighted in boldface. Combinatorial mutations shown in green affect lysines that are both acetylated and ubiquitinated. b PTM-associated sequence regions with recurrent cancer mutations (more than five SNVs). Sequence coordinates are shown on top of bars. Known cancer genes are highlighted in boldface. Mutations shown in orange are adjacent to both acetylation and ubiquitination sites. c Cancer mutations in splicing factor subunit SF3B1 (top panel) significantly associate with PTM sites (bottom panel). The ubiquitination site K700 is disrupted by the recurrent cancer mutation K700E
Fig. 2 Cancer genes with significant mutations in PTM sites. a ActiveDriver predicts cancer driver genes with significant co-occurrence of PTM sites and mutations. Genes are ranked by statistical significance. Known PTM enzymes associated with mutated PTM sites are shown on top of bars. Known cancer genes are highlighted in boldface. Combinatorial mutations shown in green affect lysines that are both acetylated and ubiquitinated. b PTM-associated sequence regions with recurrent cancer mutations (more than five SNVs). Sequence coordinates are shown on top of bars. Known cancer genes are highlighted in boldface. Mutations shown in orange are adjacent to both acetylation and ubiquitination sites. c Cancer mutations in splicing factor subunit SF3B1 (top panel) significantly associate with PTM sites (bottom panel). The ubiquitination site K700 is disrupted by the recurrent cancer mutation K700ECC BY · PubMed Central
Fig. 3 Processes and pathways with frequent cancer mutations in PTM sites. Enrichment Map shows a network of processes and pathways with over-representation of mutations in acetylation and ubiquitination sites. Nodes represent processes and pathways, and edges connect those with many common genes. Similar processes are grouped into functional themes and the most frequently mutated genes are highlighted
Fig. 3 Processes and pathways with frequent cancer mutations in PTM sites. Enrichment Map shows a network of processes and pathways with over-representation of mutations in acetylation and ubiquitination sites. Nodes represent processes and pathways, and edges connect those with many common genes. Similar processes are grouped into functional themes and the most frequently mutated genes are highlightedCC BY · PubMed Central
Fig. 4 PTM-associated network modules with patient survival correlations. a Analysis of a large protein-protein interaction network with HyperModules reveals protein modules where PTM-specific mutations correlate with reduced patient survival. The top 28 modules with lung and brain cancer mutations are shown. Node size corresponds to the number of PTM mutations per gene. b Survival-linked interaction modules often comprise overlapping sets of genes. The top 30 genes from modules are shown with colors representing modules discovered for different cancer types. c Top module of interest comprises 13 PTM-associated mutations in lung cancer. The module is indicated with an asterisk on panel (a). d Lung cancer patients with mutations in the module of interest have significantly lower survival compared to other lung cancer patients
Fig. 4 PTM-associated network modules with patient survival correlations. a Analysis of a large protein-protein interaction network with HyperModules reveals protein modules where PTM-specific mutations correlate with reduced patient survival. The top 28 modules with lung and brain cancer mutations are shown. Node size corresponds to the number of PTM mutations per gene. b Survival-linked interaction modules often comprise overlapping sets of genes. The top 30 genes from modules are shown with colors representing modules discovered for different cancer types. c Top module of interest comprises 13 PTM-associated mutations in lung cancer. The module is indicated with an asterisk on panel (a). d Lung cancer patients with mutations in the module of interest have significantly lower survival compared to other lung cancer patientsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Cited by

See all 54

Metadata

Authors
Narayan, S., Bader, G. D., & Reimand, J.
Affiliations
  • University of Toronto (CA)
  • Ontario Institute for Cancer Research (CA)
Corresponding author
  • Bader, Gary D.
  • Reimand, Jüri
Venue
Genome Medicine
Published
2016-05-12
Volume
8
Issue
1
Pages
55-55
ISSN
1756-994X (ISSN-L)
OpenAlex
W2352710988
Cited by
54
References
80
Citations by year
2026: 2 · 2025: 7 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 3 · 2019: 5 · 2018: 6 · 2017: 10 · 2016: 1
FWCI
3.05
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Genome Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • TSpace (University of Toronto) (submittedVersion)
Funders
Canadian Institutes of Health Research (MOP-84324)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
cancer driver genes, somatic mutations, acetylation sites, ubiquitination sites, post-translational modification, mutational hotspots, histone acetylation, SF3B1, TP53, AKT1, IDH1, chromatin regulation, protein-protein interaction network, patient survival, pan-cancer analysis
MeSH terms
Acetylation, Humans, Mutation, Neoplasm Proteins, Neoplasms, Protein Processing, Post-Translational, Survival Analysis, Computational Biology, Genetic Predisposition to Disease, Databases, Genetic, Gene Regulatory Networks, Ubiquitination, Mutation Rate, Protein Interaction Maps

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer. https://app.cochat.ai/papers/10.1186/s13073-016-0311-2
The paper
Narayan, S., Bader, G. D., & Reimand, J. (2016). Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer. Genome Medicine. https://doi.org/10.1186/s13073-016-0311-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.